CTLA4 and melanoma: ,65 In a small case-series of three PWH on ART receiving anti-PD-L1 for Merkel cell carcinoma or combined anti-PD-1/anti-CTLA-4 for melanoma, we recently reported that ICB led to substantial increases in cell-associated HIV RNA of up to 16-fold relative to pre-treatment levels.66